BioXcel Therapeutics Inc
Change company Symbol lookup
Select an option...
BTAI BioXcel Therapeutics Inc
BXMT Blackstone Mortgage Trust Inc
PSNL Personalis Inc
PS Pluralsight Inc
POR Portland General Electric Co
PD PagerDuty Inc
PBYI Puma Biotechnology Inc
PBF PBF Energy Inc

Health Care : Biotechnology |
Company profile

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company that is focused on the development of drugs for psychiatric disorders and rare cancers. The Company uses novel artificial intelligence (AI) for drug re-innovation processes of approved product candidates to identify new therapeutic indices. Its principal clinical development programs are BXCL501 and BXCL701. BXCL501 is a sublingual thin film formulation of dexmedetomidine (Dex) designed for the acute treatment of agitation resulting from neurological and psychiatric disorders. BXCL701 is an immuno-oncology agent designed for the treatment of prostate and pancreatic cancer.

Day's Change
-0.14 (-0.33%)
B/A Size
Day's High
Day's Low

Today's volume of 158,610 shares is on pace to be in-line with BTAI's 10-day average volume of 503,959 shares.


Upcoming Events

BTAI's fiscal year ends in December
There are no upcoming events for BTAI

Past Earnings

This page reports .
DateEvent descriptionEarnings per
share actual
estimate range
Previous year's
August 14, 2020Q2 2020 Earnings Release-$1.06-$0.83 to -$0.58-$0.54
May 12, 2020Q1 2020 Earnings Release-$0.79-$0.70 to -$0.42-$0.46
March 9, 2020Q4 2019 Earnings Release-$0.45-$0.96 to -$0.50-$0.46
November 14, 2019Q3 2019 Earnings Release-$0.57-$0.92 to -$0.56-$0.31

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

, , , Copyright © 2020. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.